UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 22, 2006
ADVENTRX Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
1-15803
|
|
84-1318182 |
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer |
| incorporation)
|
|
|
|
Identification No.) |
6725 Mesa Ridge Road, Suite 100
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(858) 552-0866
(Company’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 2.02. Results of Operations and Financial Condition
On May 22, 2006, the Company filed Amendment No. 1 to its Form 10-Q for the three months ended
March 31, 2006 previously filed on May 10, 2006, to incorporate by reference certain revised risk
factor and revised business description disclosures set forth in the Company’s Preliminary
Prospectus Supplement dated May 16, 2006 (Subject to Completion) to Prospectus dated May 8, 2006
filed with the Commission under Rule 424(b)(5) (Registration No. 333-133729) on May 16, 2006. All
risk factors and descriptions of the Company’s business found in prior filings are superseded by
these revised disclosures.
Item 8.01. Other Events
On May 22, 2006 the Company announced that it had withdrawn its proposed public offering of
15,495,867 shares of its common stock that it had previously announced on May 16, 2006.
On May 22, 2006, the Company announced that it had received FDA clearance under a Special
Protocol Assessment to initiate its CoFactor Phase III Clinical Trial. In addition, the Company
announced that it remains on track to initiate the Phase III clinical trial in Q2 2006.
The press releases issued by the Company on May 22, 2006 with respect to these matters are
included with this report as exhibits.
Item 9.01. Financial Statements and Exhibits.
| (d) |
|
The exhibit list required by this item is incorporated by reference to the Exhibit Index
filed as part of this report. |